384 related articles for article (PubMed ID: 23072611)
1. Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal V; Alayoubi A; Siddiqui A; Nazzal S
Drug Dev Ind Pharm; 2013 Nov; 39(11):1681-9. PubMed ID: 23072611
[TBL] [Abstract][Full Text] [Related]
2. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
[TBL] [Abstract][Full Text] [Related]
3. Development of meloxicam formulations utilizing ternary complexation for solubility enhancement.
Awasthi SS; Kumar TG; Manisha P; Preeti Y; Kumar SS
Pak J Pharm Sci; 2011 Oct; 24(4):533-8. PubMed ID: 21959817
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meloxicam administered as regular and fast dissolving formulations to the rat: influence of gastrointestinal dysfunction on the relative bioavailability of two formulations.
Aghazadeh-Habashi A; Jamali F
Eur J Pharm Biopharm; 2008 Nov; 70(3):889-94. PubMed ID: 18715548
[TBL] [Abstract][Full Text] [Related]
5. The effect of the composition of a fixed dose combination on bioequivalence results.
Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
[TBL] [Abstract][Full Text] [Related]
6. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization.
Ah YC; Choi JK; Choi YK; Ki HM; Bae JH
Int J Pharm; 2010 Jan; 385(1-2):12-9. PubMed ID: 19833177
[TBL] [Abstract][Full Text] [Related]
7. Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations.
Hanft G; Türck D; Scheuerer S; Sigmund R
Inflamm Res; 2001 Mar; 50 Suppl 1():S35-7. PubMed ID: 11339520
[TBL] [Abstract][Full Text] [Related]
8. In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets.
Gao C; Huang J; Jiao Y; Shan L; Liu Y; Li Y; Mei X
Int J Pharm; 2006 Sep; 322(1-2):104-12. PubMed ID: 16806752
[TBL] [Abstract][Full Text] [Related]
9. Soft, chewable gelatin-based pharmaceutical oral formulations: a technical approach.
Dille MJ; Hattrem MN; Draget KI
Pharm Dev Technol; 2018 Jun; 23(5):504-511. PubMed ID: 28532266
[TBL] [Abstract][Full Text] [Related]
10. Tablet formulation containing meloxicam and beta-cyclodextrin: mechanical characterization and bioavailability evaluation.
Ghorab MM; Abdel-Salam HM; El-Sayad MA; Mekhel MM
AAPS PharmSciTech; 2004 Jul; 5(4):e59. PubMed ID: 15760056
[TBL] [Abstract][Full Text] [Related]
11. Improved absorption of meloxicam via salt formation with ethanolamines.
Han HK; Choi HK
Eur J Pharm Biopharm; 2007 Jan; 65(1):99-103. PubMed ID: 16919925
[TBL] [Abstract][Full Text] [Related]
12. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.
Ambrus R; Kocbek P; Kristl J; Sibanc R; Rajkó R; Szabó-Révész P
Int J Pharm; 2009 Nov; 381(2):153-9. PubMed ID: 19616609
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.
Vivancos M; Barker J; Engbers S; Fischer C; Frederick J; Friedt H; Rybicka JM; Stastny T; Banse H; Cribb AE
Can Vet J; 2015 Jul; 56(7):730-6. PubMed ID: 26130835
[TBL] [Abstract][Full Text] [Related]
14. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
[TBL] [Abstract][Full Text] [Related]
15. Particle engineering/different film approaches for earlier absorption of meloxicam.
Farid M; El-Setouhy DA; El-Nabarawi MA; El-Bayomi T
Drug Deliv; 2016 Sep; 23(7):2309-2317. PubMed ID: 25431841
[TBL] [Abstract][Full Text] [Related]
16. Preparation of meloxicam-β-cyclodextrin-polyethylene glycol 6000 ternary system: characterization, in vitro and in vivo bioavailability.
Radia O; Rogalska E; Moulay-Hassane G
Pharm Dev Technol; 2012; 17(5):632-7. PubMed ID: 21428700
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.
Noble G; Edwards S; Lievaart J; Pippia J; Boston R; Raidal SL
J Vet Intern Med; 2012; 26(5):1192-201. PubMed ID: 22860573
[TBL] [Abstract][Full Text] [Related]
18. Development of meloxicam in situ implant formulation by quality by design principle.
Ibrahim HM; Ahmed TA; Hussain MD; Rahman Z; Samy AM; Kaseem AA; Nutan MT
Drug Dev Ind Pharm; 2014 Jan; 40(1):66-73. PubMed ID: 23298324
[TBL] [Abstract][Full Text] [Related]
19. Dissolution and powder flow characterization of solid self-emulsified drug delivery system (SEDDS).
Agarwal V; Siddiqui A; Ali H; Nazzal S
Int J Pharm; 2009 Jan; 366(1-2):44-52. PubMed ID: 18832019
[TBL] [Abstract][Full Text] [Related]
20. Development of solid SEDDS, VII: Effect of pore size of silica on drug release from adsorbed self-emulsifying lipid-based formulations.
Gumaste SG; Serajuddin ATM
Eur J Pharm Sci; 2017 Dec; 110():134-147. PubMed ID: 28506870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
